COR
Cencora, Inc.
$303.44
+0.98 (+0.32%)
At close · Jul 10
Market Cap
$58.85B
Shares
194,561,060
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$321.33B
+9.3%
FY2025
Net Income
$1.55B
+3%
FY2025
Gross Margin
3.57%
+0.2pp
FY2025
Operating Margin
0.82%
+0.1pp
FY2025
Diluted EPS
$7.96
+5.7%
FY2025
Operating Cash Flow
$3.88B
+11.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $328.68B | $321.33B | $293.96B | $262.17B | $238.59B | $213.99B | $189.89B | $179.59B | $167.94B | $153.14B | $146.85B | $135.96B | $119.57B | $87.96B | $78.08B | $78.7B | $76.5B | $71.76B | $70.19B | $65.67B | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | -$76.86M | -$73.9M | -$92.57M | -$76.15M | -$71.79M | -$58.31M | $64.5M | — | |
| — | $316.16B | $309.85B | $284.05B | $253.21B | $230.29B | $207.05B | $184.7B | $174.45B | $163.33B | $148.6B | $142.58B | $132.43B | $116.59B | $85.45B | $75.45B | $76.24B | $74.22B | $69.66B | $68.14B | $63.45B | |
| — | $12.52B | $11.48B | $9.91B | $8.96B | $8.3B | $6.94B | $5.19B | $5.14B | $4.61B | $4.55B | $4.27B | $3.53B | $2.98B | $2.51B | $2.63B | $2.46B | $2.28B | $2.1B | $2.05B | $2.22B | |
| — | — | 3.57% | 3.37% | 3.42% | 3.48% | 3.24% | 2.73% | 2.86% | 2.75% | 2.97% | 2.91% | 2.6% | 2.49% | 2.85% | 3.37% | 3.12% | 2.98% | 2.93% | 2.92% | 3.38% | |
| — | $7.19B | $6.49B | $5.66B | $5.31B | $4.85B | $3.59B | $2.77B | $2.66B | $2.46B | $2.13B | $2.09B | $1.91B | $1.58B | $1.33B | $1.15B | $1.14B | $1.11B | $1.12B | $1.12B | $1.34B | |
| — | $496.42M | $556.93M | $663.47M | $553.56M | $307.3M | $178.35M | $110.88M | $167.44M | $181.16M | $160.5M | $152.49M | $56.49M | $25.96M | $27.14M | $21.55M | $12.6M | $12.49M | $15.42M | $17.13M | $16.45M | |
| — | — | $1.05B | $1.09B | $963.9M | $693.9M | $505.17M | $391.06M | $462.41M | $465.13M | $397.6M | $364.74M | $248.64M | $188.68M | $162.19M | $134.38M | $101.36M | $79.5M | — | — | — | |
| — | $185.84M | $229.42M | $233.63M | $229.88M | $63.5M | $82.32M | $6.81B | $330.47M | $183.52M | $959.33M | $102.91M | $37.89M | $8.19M | $23.47M | $44.14M | $23.57M | -$4.48M | $5.41M | $12.38M | $2.07M | |
| — | — | $6.99B | $6.09B | $5.72B | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $2.79B | $2.63B | $2.18B | $2.34B | $2.37B | $2.35B | -$5.14B | $1.11B | $1.44B | $1.06B | $1.53B | $422.22M | $782.09M | $898.4M | $1.3B | $1.19B | $1.09B | $883.75M | $827.86M | $788.74M | |
| — | — | 0.82% | 0.74% | 0.89% | 0.99% | 1.1% | -2.7% | 0.62% | 0.86% | 0.69% | 1.04% | 0.31% | 0.65% | 1.02% | 1.67% | 1.51% | 1.42% | 1.23% | 1.18% | 1.2% | |
| — | — | $3.68B | $3.27B | $3.3B | $3.06B | $2.86B | -$4.74B | $1.57B | $1.91B | $1.46B | $1.89B | $670.86M | $970.77M | $1.06B | $1.44B | $1.29B | $1.17B | — | — | — | |
| — | $1.09B | -$78.72M | -$14.28M | $49.04M | $27.35M | $41.74M | $1.58M | $12.95M | -$25.47M | $2.73M | $5.05M | -$13.6M | $4.36M | -$44K | $5.83M | $4.62M | -$3.37M | -$1.37M | -$2.03M | -$3M | |
| — | $3.51B | $2.26B | $2B | $2.16B | $2.18B | $2.22B | -$5.29B | $967.11M | $1.18B | $917.89M | $1.39B | $268.96M | $669.86M | $824.46M | $1.22B | $1.12B | $1.01B | $824.07M | $761.34M | $753.49M | |
| — | $954.11M | $690.52M | $484.7M | $428.26M | $516.52M | $677.25M | -$1.89B | $112.97M | -$438.47M | $553.4M | -$37.02M | $407.13M | $388.09M | $331.02M | $455.51M | $420.49M | $385.24M | $312.22M | $292.27M | $278.69M | |
| — | $2.55B | $1.55B | $1.51B | $1.75B | $1.7B | $1.54B | -$3.41B | $855.37M | $1.66B | $364.48M | $1.43B | -$138.17M | $274.23M | $433.71M | $718.99M | $706.62M | $636.75M | $503.4M | $250.56M | $469.17M | |
| — | — | 0.48% | 0.51% | 0.67% | 0.71% | 0.72% | -1.8% | 0.48% | 0.99% | 0.24% | 0.97% | -0.1% | 0.23% | 0.49% | 0.92% | 0.9% | 0.83% | 0.7% | 0.36% | 0.71% | |
| — | $3.66M | $13.65M | $10.15M | -$12.72M | -$32.28M | $4.68M | $9.16M | -$1.23M | -$42.51M | $0 | $0 | — | — | — | — | — | — | — | — | — | |
| — | $2.79B | $1.64B | $1.92B | $2.17B | $313.29M | $1.2B | -$3.41B | $822.65M | $1.68B | $382.94M | $1.45B | -$222.45M | $257.67M | $430.88M | $736.47M | $699.07M | — | — | — | — | |
| USD/shares | — | — | $8.02 | $7.60 | $8.62 | $8.15 | $7.48 | -$16.65 | $4.07 | $7.61 | $1.67 | $6.73 | -$0.63 | $1.21 | $1.88 | $2.84 | $2.59 | $2.26 | $1.67 | $0.78 | $1.27 |
| USD/shares | $17.65 – $17.90* | — | $7.96 | $7.53 | $8.53 | $8.04 | $7.39 | -$16.65 | $4.04 | $7.53 | $1.64 | $6.32 | -$0.63 | $1.16 | $1.84 | $2.80 | $2.54 | $2.22 | $1.66 | $0.77 | $1.25 |
| shares | — | — | 193.82M | 198.5M | 202.51M | 208.47M | 205.92M | 204.78M | 210.17M | 217.87M | 218.38M | 212.21M | 217.79M | 227.37M | 231.07K | 252.91M | 272.47M | 282.26M | 300.57M | 321.28M | 370.36M |
| shares | — | — | 195.21M | 200.28M | 204.59M | 211.21M | 208.47M | 204.78M | 211.84M | 220.34M | 221.6M | 225.96M | 217.79M | 235.41M | 235.35K | 256.9M | 277.72M | 287.25M | 302.75M | 324.92M | 375.77M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $16.14B in buybacks, $4.79B in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
0.21×
EV/EBIT
24.83×
P/E (TTM)
23.18×
Medical Distribution median 23.18×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 | 2018-09-30 |
|---|---|---|---|---|---|---|---|---|
| US Healthcare Solutions | $290,982,023,000 | $265,339,427,000 | $234,759,218,000 | $212,100,202,000 | $202,461,545,000 | — | — | — |
| International Healthcare Solutions | $30,366,323,000 | $28,627,542,000 | $27,418,679,000 | $26,491,673,000 | $11,529,629,000 | — | — | — |
| Global Commercialization Services | — | — | — | — | — | $3,308,640,000 | — | $2,542,971,000 |
| International Healthcare Solutions | — | — | — | — | — | $3,508,106,000 | — | — |
| MWI Animal Health | — | — | — | — | — | $4,216,462,000 | — | $3,789,759,000 |
| Pharmaceutical Distribution | — | — | — | — | — | $182,467,189,000 | $172,813,537,000 | $161,699,343,000 |
| All Other Segments | — | — | — | — | — | $7,525,102,000 | $6,868,341,000 | $6,332,730,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 | 2018-09-30 |
|---|---|---|---|---|---|---|---|---|
| US Healthcare Solutions | $3,574,699,000 | $2,934,877,000 | $2,596,559,000 | $2,456,972,000 | $2,257,918,000 | — | — | — |
| International Healthcare Solutions | $648,274,000 | $713,379,000 | $692,562,000 | $706,458,000 | $390,286,000 | — | — | — |
| International Healthcare Solutions | — | — | — | $706,458,000 | $390,286,000 | $184,380,000 | — | — |
| Pharmaceutical Distribution | — | — | — | — | $2,041,072,000 | $1,807,001,000 | $1,671,251,000 | $1,626,748,000 |
| US Healthcare Solutions | — | — | — | $2,456,972,000 | $2,257,918,000 | $2,020,067,000 | — | — |
| All Other Segments | — | — | — | — | $614,973,000 | $400,139,000 | $380,660,000 | $355,091,000 |
Operating Margin by Segment (%)
| Component | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 | 2018-09-30 |
|---|---|---|---|---|---|---|---|---|
| US Healthcare Solutions | 1.2% | 1.1% | 1.1% | 1.2% | 1.1% | — | — | — |
| International Healthcare Solutions | 2.1% | 2.5% | 2.5% | 2.7% | 3.4% | — | — | — |
| International Healthcare Solutions | — | — | — | — | — | 5.3% | — | — |
| Pharmaceutical Distribution | — | — | — | — | — | 1% | 1% | 1% |
| All Other Segments | — | — | — | — | — | 5.3% | 5.5% | 5.6% |
Key facts
CIK
1140859
CUSIP
03073E105
13F (30d)
90 filings
63 filers
Visit website
Investor relations